Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Carboxymethylcellulose and Glycerin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Carboxymethylcellulose sodium and Glycerin | DRUG | - |
Inclusion Criteria: * Mild, Moderate, or Severe Dry Eye Symptoms and current eye drop use; * Reduced tear stability or tear production Exclusion Criteria: * NONE
Carboxymethylcellulose and Glycerin is an investigational lubricant eye drop being studied for the treatment of dry eye. It is a small molecule product in the ophthalmology therapeutic area. The drug is currently in Phase 2 clinical development and is not approved by the FDA.
Carboxymethylcellulose and Glycerin is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational lubricant eye drop for dry eye.
Carboxymethylcellulose and Glycerin is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The product is being studied as a lubricant eye drop for patients with dry eye, and its safety and efficacy are still being evaluated in clinical trials.
Carboxymethylcellulose and Glycerin has one completed clinical trial, identified as NCT00243711. This was a multi-center, randomized, double-blind study conducted in the United States to evaluate the efficacy and safety of an investigational lubricant eye drop in 286 participants with dry eye. The trial enrolled adults aged 18 years and older.
Carboxymethylcellulose and Glycerin is a specific investigational lubricant eye drop formulation being developed by AbbVie. It is not known to be the same as any other marketed product. The drug is currently in Phase 2 clinical trials for dry eye, and its unique composition is being evaluated for safety and efficacy.